Dose escalation with repeated intrathecal injections of 131I-labelled MAbs for the treatment of central nervous system malignancies.

We have previously demonstrated a 33% response rate in patients with primitive neurectodermal tumours after the direct injection of 131I-monoclonal antibodies (MAbs) into the cerebrospinal fluid (CSF). Dose-limiting toxicity is myelosuppression due to the passage of the radioimmunoconjugate from the...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
Main Authors: Kemshead, J. T., Hopkins, K., Pizer, B., Papanastassiou, V., Coakham, H., Bullimore, J., Chandler, C.
Format: Artigo
Jezik:Inglês
Izdano: Nature Publishing Group 1998
Teme:
Research Article
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC2150406/
https://ncbi.nlm.nih.gov/pubmed/9649153
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki